Left amygdala activation

Left amygdala activation refers to the physiological and metabolic response of the left amygdaloid complex, a key limbic system structure primarily involved in emotional processing and the appraisal of threat-related stimuli (LeDoux, 2000). While it is not a molecular target such as a protein or enzyme, its activation levels are frequently utilized as a functional biomarker in neuropsychiatric research to evaluate the efficacy of pharmacological interventions. Excessive or dysregulated activation in this region is a well-documented hallmark of various affective and anxiety-related conditions, including Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) (Shin & Liberzon, 2010). Therapeutic agents like Selective Serotonin Reuptake Inhibitors (SSRIs) and benzodiazepines have been shown to normalize or reduce hyperactivation in the amygdala, often correlating with the alleviation of clinical symptoms (Harmer et al., 2006; Paulus et al., 2005). In modern drug development, functional Magnetic Resonance Imaging (fMRI) is used to monitor this activation as a surrogate endpoint for drug activity in the central nervous system. Consequently, the modulation of the neural circuits associated with left amygdala activation remains a central focus of neuropsychopharmacology.

Other names

Left amygdala reactivityLeft amygdalar responseLeft amygdala BOLD signalFunctional activation of the left amygdala

Pharmacological modulation of neurotransmitter systems, such as increasing serotonergic tone or enhancing GABAergic inhibition, to attenuate the hyper-responsivity of neural circuits within the amygdaloid complex (Stein et al., 2007; Paulus et al., 2005).